Pre-clinical drug tests in the mdx mouse as a model of dystrophinopathies: an overview - Wikidata - awgldk - TriplyDB

Pre-clinical drug tests in the mdx mouse as a model of dystrophinopathies: an overview

Pre-clinical drug tests in the mdx mouse as a model of dystrophinopathies: an overview

http://www.wikidata.org/entity/Q26849430

about

Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery Oxidative Stress-Mediated Skeletal Muscle Degeneration: Molecules, Mechanisms, and Therapies The role of fibrosis in Duchenne muscular dystrophy Nutraceuticals and Their Potential to Treat Duchenne Muscular Dystrophy: Separating the Credible from the Conjecture New pathobiochemical insights into dystrophinopathy from the proteomics of senescent mdx mouse muscle Fluoxetine prevents dystrophic changes in a zebrafish model of Duchenne muscular dystrophy.Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials Diapocynin, a dimer of the NADPH oxidase inhibitor apocynin, reduces ROS production and prevents force loss in eccentrically contracting dystrophic muscle Prednisolone attenuates improvement of cardiac and skeletal contractile function and histopathology by lisinopril and spironolactone in the mdx mouse model of Duchenne muscular dystrophy.Increased taurine in pre-weaned juvenile mdx mice greatly reduces the acute onset of myofibre necrosis and dystropathology and prevents inflammation.Turn up the power - pharmacological activation of mitochondrial biogenesis in mouse models.Dystrophic muscle environment induces changes in cell plasticity.Andrographolide attenuates skeletal muscle dystrophy in mdx mice and increases efficiency of cell therapy by reducing fibrosis.Myofiber-specific inhibition of TGFβ signaling protects skeletal muscle from injury and dystrophic disease in mice.The Rag2⁻Il2rb⁻Dmd⁻ mouse: a novel dystrophic and immunodeficient model to assess innovating therapeutic strategies for muscular dystrophies.Beneficial effects of high dose taurine treatment in juvenile dystrophic mdx mice are offset by growth restriction.Duchenne and Becker Muscular Dystrophies: A Review of Animal Models, Clinical End Points, and Biomarker Quantification.

P2860

Q26744730-5215996E-1339-481C-80AE-41610D338AD7 Q26769962-8F6DB305-27A6-4713-A100-7900AB3D3669 Q27024049-3B394612-D853-4B8B-8201-9FED12764B32 Q28072269-4D9D5D5C-D45C-4966-9A4C-2D0AD2965542 Q33703934-33C72203-6486-4A8E-A222-C90FF3210E2C Q33991780-4A23F2CF-CE42-434B-B278-E8CEB6BDE42D Q34152280-1B0A1710-34CB-4BCD-B710-23536246F597 Q34444163-992010E0-FD3B-4F37-A693-26FE314AB223 Q35097376-EDC492EE-E5CD-4E54-940A-EFDD8EBFAAA2 Q36146630-C2B0611C-C5E4-40FE-AB38-C357572E59EF Q37686240-AF7B8D47-35E1-4E2E-AA70-19E2950D6FCE Q39027193-5F516B9E-E94E-41BB-985A-B7A373D0943D Q39629598-75C22CB6-2107-404F-A2CF-D6DC65AD84AE Q41979450-28999B91-F331-4D3B-9B2E-ED5E16ED5CF3 Q42934738-3E7638AC-4D1D-4D60-B2C6-E9FCAEE72980 Q43845526-433E82DE-768A-4AAD-BA0A-2B1E59055B6D Q47704855-8A88C716-1C64-4686-B7FB-85ADB00ED253

P2860

Pre-clinical drug tests in the mdx mouse as a model of dystrophinopathies: an overview

http://www.wikidata.org/entity/Q26849430

description

2012 nî lūn-bûn

@nan

2012 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Pre-clinical drug tests in the mdx mouse as a model of dystrophinopathies: an overview

@ast

Pre-clinical drug tests in the mdx mouse as a model of dystrophinopathies: an overview

@en

Pre-clinical drug tests in the mdx mouse as a model of dystrophinopathies: an overview

@nl

type

label

Pre-clinical drug tests in the mdx mouse as a model of dystrophinopathies: an overview

@ast

Pre-clinical drug tests in the mdx mouse as a model of dystrophinopathies: an overview

@en

Pre-clinical drug tests in the mdx mouse as a model of dystrophinopathies: an overview

@nl

prefLabel

Pre-clinical drug tests in the mdx mouse as a model of dystrophinopathies: an overview

@ast

Pre-clinical drug tests in the mdx mouse as a model of dystrophinopathies: an overview

@en

Pre-clinical drug tests in the mdx mouse as a model of dystrophinopathies: an overview

@nl

P1433

Q26849430-BE92A76F-38B8-4541-8C09-0DFADDE1C2D7

P1476

Q26849430-89A179A3-6C5D-4800-ACC5-5840A3B793AD

P2093

Q26849430-4CCDE557-DE23-408F-AA5E-EE19E1F24680

P275

Q26849430-C1FC6EFB-D4DE-4A48-8412-C3A16BD7A243

P2860

Q26849430-03C2856B-A73D-431E-8112-DE7EAEACB924

Q26849430-042BF4CD-E88F-4AEF-A4FD-863652485465

Q26849430-053F5521-33B1-4A0E-B6A5-7907719A49D7

Q26849430-0CF281FE-922B-4D1E-BF34-3551AF9E5058

Q26849430-11168657-AE1D-494C-90BC-C18E288EDEF2

Q26849430-11CCF1C3-B502-4B27-A0FD-E51CDAD71BA1

Q26849430-1336E2A2-66D8-4995-B947-2A4D36D6D821

Q26849430-142D86FF-212C-488F-A370-A81F3871EE98

Q26849430-155EA231-2986-4854-A974-053C2D3DF028

Q26849430-1AC29723-454E-4F47-AB37-88587886874A

P304

Q26849430-2890254F-21B6-4B2A-94E1-1704747C2D98

P31

Q26849430-72F90DDF-20ED-4D6C-9038-D675D278498E

P3181

Q26849430-A221A75A-1F00-47A2-8653-0553766F51C1

P407

Q26849430-C57C402D-107F-4875-971B-1D4EA4134E03

P433

Q26849430-7213850D-E488-43CB-8C4C-DA8652C14189

P478

Q26849430-C2F85D5F-F2C5-4EEE-82B7-2FB670802842

P5008

Q26849430-743388E3-ACF9-4198-B213-4FD3617E9F1B

P577

Q26849430-76A2E52D-E248-4B3B-B2EB-FDFFC319B062

P698

Q26849430-445B48F6-54D7-4186-ABB4-412A1391ACA6

P921

Q26849430-0542C085-0B40-48EB-9D09-422E75846E55

Q26849430-471E134E-5F06-4C4E-A583-397E57DBE9D0

Q26849430-646AECED-ABED-408C-9E7B-35311255AED6

Q26849430-C261B479-985E-473F-9010-C5349D86206C

P932

Q26849430-937D78DC-6939-4628-B31C-E67AEED545EC

P3181

P1433

P1476

Pre-clinical drug tests in the mdx mouse as a model of dystrophinopathies: an overview

@en

P2093

Annamaria De Luca

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported

P2860

Long-term blinded placebo-controlled study of SNT-MC17/idebenone in the dystrophin deficient mdx mouse: cardiac protection and improved exercise performance

Rescue of dystrophic skeletal muscle by PGC-1α involves a fast to slow fiber type shift in the mdx mouse

Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice

Making fast-twitch dystrophic muscles bigger protects them from contraction injury and attenuates the dystrophic pathology.

Membrane sealant Poloxamer P188 protects against isoproterenol induced cardiomyopathy in dystrophin deficient mice.

Preclinical drug trials in the mdx mouse: assessment of reliable and sensitive outcome measures.

Co-administration of ibuprofen and nitric oxide is an effective experimental therapy for muscular dystrophy, with immediate applicability to humans.

Sildenafil reverses cardiac dysfunction in the mdx mouse model of Duchenne muscular dystrophy.

Molecular pathophysiology and targeted therapeutics for muscular dystrophy.

Biglycan recruits utrophin to the sarcolemma and counters dystrophic pathology in mdx mice

P304

40-47

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1741074

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2012-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22655516

http://www.w3.org/2001/XMLSchema#string

P921

Duchenne muscular dystrophy

membrane proteins

cytoskeletal proteins

contractile proteins

P932

3440805

http://www.w3.org/2001/XMLSchema#string